Thomas Lönngren, former executive director of the European Medicines Agency, has joined the NDA Group, as a strategic advisor to the group’s new regulatory and market access business called NDA Advisory Services Ltd..
The new business group will address the problems facing companies as they try to meet the requirements of both drug regulators and health technology bodies. “The route to market is extremely complex and expensive and many products fail because companies do not fully address the need to demonstrate the quality, safety and efficacy of their products and also adapt to the European reimbursement systems,” said Tony Baker, vice president of the NDA Group.
Copyright 2010 Evernow Publishing Ltd